25 results on '"Smith, Kenneth"'
Search Results
2. Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18–64 years of age
3. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults
4. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults
5. Impact of seasonal influenza vaccination in the presence of vaccine interference
6. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults
7. Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study
8. Antigen nature and complexity influence human antibody light chain usage and specificity
9. Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis
10. Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis
11. Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
12. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50–64 years compared to the US general population
13. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults
14. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization
15. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups
16. The potential economic value of a hookworm vaccine
17. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine
18. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds
19. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza
20. The potential economic value of a Staphylococcus aureus vaccine for neonates
21. The timing of influenza vaccination for older adults (65 years and older)
22. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis
23. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population
24. Corrigendum to “Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older” [Vaccine 42 (2024) 3024–3032]
25. Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.